🇪🇺 Corectim in European Union

EMA authorised Corectim on 19 September 2024

Marketing authorisation

EMA — authorised 19 September 2024

  • Application: EMEA/H/C/006109
  • Marketing authorisation holder: LEO Pharma A/S
  • Local brand name: Anzupgo
  • Indication: Anzupgo is indicated for the treatment of moderate to severe chronic hand eczema (CHE)
  • Status: approved

The European Medicines Agency (EMA) approved Corectim (local brand name: Anzupgo) for the treatment of moderate to severe chronic hand eczema (CHE). The marketing authorisation was granted to LEO Pharma A/S on 19 September 2024. This approval was obtained through the standard expedited pathway.

Read official source →

Corectim in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is Corectim approved in European Union?

Yes. EMA authorised it on 19 September 2024.

Who is the marketing authorisation holder for Corectim in European Union?

LEO Pharma A/S holds the EU marketing authorisation.